Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
© 2021 The Author(s)..
BACKGROUND: The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experienced a more protracted disease length. Previous reports have described successful use of convalescent plasma, however there is a paucity of information around the use of the REGN-COV2 antibody cocktail in these patients.
CASE REPORT: A patient with XLA was admitted to hospital with COVID-19 and remained persistently symptomatic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab positivity despite treatment with Remdesivir and dexamethasone. Attempts at modulating the immune response with anakinra were unsuccessful. Consent for compassionate use of REGN-COV2 was obtained with administration taking place on day 87 of his illness. This was followed by a period of convalescence and SARS-CoV-2 nasopharyngeal swab negativity. As a consequence of prolonged immunosuppression, the patient developed pneumocystis pneumonia.
CONCLUSION: This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged immunosuppression and delayed treatment. We propose that this may be of particular significance given the capacity of SARS-CoV-2 to develop advantageous mutations in a chronically infected host.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical infection in practice - 12(2021) vom: 18. Nov., Seite 100089 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyen, Hanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Agammaglobulinemia |
|---|
| Anmerkungen: |
Date Revised 01.11.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.clinpr.2021.100089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329700715 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329700715 | ||
| 003 | DE-627 | ||
| 005 | 20231225205701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinpr.2021.100089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329700715 | ||
| 035 | |a (NLM)34426799 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Hanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Author(s). | ||
| 520 | |a BACKGROUND: The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experienced a more protracted disease length. Previous reports have described successful use of convalescent plasma, however there is a paucity of information around the use of the REGN-COV2 antibody cocktail in these patients | ||
| 520 | |a CASE REPORT: A patient with XLA was admitted to hospital with COVID-19 and remained persistently symptomatic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab positivity despite treatment with Remdesivir and dexamethasone. Attempts at modulating the immune response with anakinra were unsuccessful. Consent for compassionate use of REGN-COV2 was obtained with administration taking place on day 87 of his illness. This was followed by a period of convalescence and SARS-CoV-2 nasopharyngeal swab negativity. As a consequence of prolonged immunosuppression, the patient developed pneumocystis pneumonia | ||
| 520 | |a CONCLUSION: This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged immunosuppression and delayed treatment. We propose that this may be of particular significance given the capacity of SARS-CoV-2 to develop advantageous mutations in a chronically infected host | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Agammaglobulinemia | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a REGN-COV2 | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a SARS-CoV2 | |
| 700 | 1 | |a Salkeld, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Sangita |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infection in practice |d 2019 |g 12(2021) vom: 18. Nov., Seite 100089 |w (DE-627)NLM30486448X |x 2590-1702 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:18 |g month:11 |g pages:100089 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinpr.2021.100089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 18 |c 11 |h 100089 | ||